Acorda Therapeutics Inc. (ACOR)

3.49
NASDAQ : Health Technology
Prev Close 3.39
Day Low/High 3.34 / 3.58
52 Wk Low/High 2.27 / 21.63
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 48.08M
Market Cap 162.99M
EPS 0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acorda Receives Positive CHMP Opinion For INBRIJA™ (levodopa Inhalation Powder)

Acorda Receives Positive CHMP Opinion For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending INBRIJA's approval by the European Commission (EC).

First Week Of ACOR September 20th Options Trading

First Week Of ACOR September 20th Options Trading

Investors in Acorda Therapeutics Inc saw new options begin trading this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Acorda Second Quarter 2019 Update:  Webcast/Conference Call Scheduled For August 1, 2019

Acorda Second Quarter 2019 Update:  Webcast/Conference Call Scheduled For August 1, 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast to report its second quarter 2019 update and financial results on Thursday, August 1 at 4:30 p.

Acorda Therapeutics Enters Oversold Territory (ACOR)

Acorda Therapeutics Enters Oversold Territory (ACOR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting ACOR Put And Call Options For August 16th

Interesting ACOR Put And Call Options For August 16th

Investors in Acorda Therapeutics Inc saw new options become available today, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Acorda Therapeutics Debuts Art Exhibition Inspired By People With Parkinson's At The 5th World Parkinson Congress

Acorda Therapeutics Debuts Art Exhibition Inspired By People With Parkinson's At The 5th World Parkinson Congress

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that it will debut an art gallery inspired by people with Parkinson's (PwP) at the 5 th World Parkinson Congress (WPC) in Kyoto, Japan.

RSI Alert: Acorda Therapeutics (ACOR) Now Oversold

RSI Alert: Acorda Therapeutics (ACOR) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of January 2020 Options Trading For Acorda Therapeutics (ACOR)

First Week Of January 2020 Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options become available this week, for the January 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico, Ph.

Acorda Therapeutics To Present At Jefferies 2019 Healthcare Conference

Acorda Therapeutics To Present At Jefferies 2019 Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.

Acorda Provides Update For First Quarter Ended March 31, 2019

Acorda Provides Update For First Quarter Ended March 31, 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) provided a financial and pipeline update for the quarter ended March 31, 2019.

Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled For May 2, 2019

Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled For May 2, 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.

Acorda Therapeutics Enters Oversold Territory (ACOR)

Acorda Therapeutics Enters Oversold Territory (ACOR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of ACOR May 17th Options Trading

First Week Of ACOR May 17th Options Trading

Investors in Acorda Therapeutics Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Acorda To Present New Long-Term Data For INBRIJA™ (levodopa Inhalation Powder) At Academy Of Managed Care Pharmacy Annual Meeting

Acorda To Present New Long-Term Data For INBRIJA™ (levodopa Inhalation Powder) At Academy Of Managed Care Pharmacy Annual Meeting

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego.

Acorda Therapeutics Announces Management Changes

Acorda Therapeutics Announces Management Changes

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that Andrew Hindman, Chief Business Officer, will transition out of the Company over the coming months.

Acorda To Present At Oppenheimer's 29th Annual Healthcare Conference

Acorda To Present At Oppenheimer's 29th Annual Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Andrew Hindman, Acorda's Chief Business Officer, will present at the Oppenheimer & Co.

Acorda Therapeutics Announces Commercial Launch Of INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics Announces Commercial Launch Of INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States.

Acorda Therapeutics To Present At Cowen Annual Health Care Conference

Acorda Therapeutics To Present At Cowen Annual Health Care Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.

Acorda Therapeutics To Present At Leerink Global Healthcare Conference

Acorda Therapeutics To Present At Leerink Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Andrew Hindman, Acorda's Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2018

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2018

Acorda Therapeutics, Inc. (NASDAQ: ACOR) provided financial and pipeline updates for the fourth quarter and full year ended December 31, 2018.

Acorda Appoints Peter S. Carbone Senior Vice President, Quality

Acorda Appoints Peter S. Carbone Senior Vice President, Quality

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S.

Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled For February 14, 2019

Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled For February 14, 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results on Thursday, February 14 at 4:30 p.

First Week Of ACOR March 15th Options Trading

First Week Of ACOR March 15th Options Trading

Investors in Acorda Therapeutics Inc saw new options become available this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new March 15th contracts and identified one put and one call contract of particular interest.

Acorda Announces The Lancet Neurology Publication Of Phase 3 Data For INBRIJA™ (levodopa Inhalation Powder)

Acorda Announces The Lancet Neurology Publication Of Phase 3 Data For INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that  The Lancet Neurology published results from SPAN℠-PD, the Phase 3 pivotal efficacy trial of INBRIJA™ (levodopa inhalation powder), also referred to as CVT-301.

Acorda Provides 2018 Highlights And 2019 Guidance At J.P. Morgan Healthcare Conference

Acorda Provides 2018 Highlights And 2019 Guidance At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided 2018 highlights, 2019 guidance and commercialization plans for INBRIJA at the 37 th Annual J.

First Week Of February 15th Options Trading For Acorda Therapeutics (ACOR)

First Week Of February 15th Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Acorda Therapeutics Announces FDA Approval Of INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics Announces FDA Approval Of INBRIJA™ (levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.

TheStreet Quant Rating: D (Sell)